News briefs: Meda's Edluar; Debiopharm/Ascepion; Mallinckrodt/Horizon

19 June 2012

Swedish drugmaker Meda AB (OMX: MEDA A) says that is Edluar, an oral sublingual formulation of zolpidem, has received registration approval in Europe via the decentralized procedure with Sweden acting as reference member state. Edluar is used for treating sleep disorders. National registration processes will now follow in each country., the company stated, noting that the first launches are expected early next year.

Edluar, for which Meda gained global rights from fellow Swedish firm Orexo in 2008, was launched in the US market in 2009 and the launch in Canada (brand Sublinox) started early 2012. Edluar/Sublinox uses a unique, patented sublingual tablet formulation for fast and effective absorption. “With this approval, we cover the key markets. We will now continue the registration process on other interesting markets”, said Anders Lonner, chief executive of Meda.

Debiopharm and Ascepion Pharma collaborate

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK